Saruwatari Junji, Nakagawa Kazuko, Ishizaki Takashi
Department of Pharmacology and Therapeutics, Graduate School of Clinical Pharmacy, Kumamoto University.
Nihon Rinsho. 2002 Jan;60(1):58-63.
Genetic polymorphisms in drug-metabolizing enzymes are responsible for interindividual differences in the disposition of numerous drugs. The poor metabolizers (PMs) are derived from mutant alleles of cytochrome P450 (CYP), and those PMs are more susceptible to the development of adverse drug reactions, when the parent drug is pharmacologically active, or are showing a lack of therapeutic efficacy, when a prodrug is administered and its active metabolite(s) is not formed. This article reviews the basic knowledge of genetic polymorphisms of CYP-related drug-metabolizing enzymes and the clinical implications for a safer and more efficient drug therapy.
药物代谢酶中的基因多态性是导致多种药物处置存在个体差异的原因。慢代谢者（PMs）源自细胞色素P450（CYP）的突变等位基因，当母体药物具有药理活性时，这些慢代谢者更容易发生药物不良反应；而当给予前体药物且其活性代谢物未形成时，则表现出治疗效果不佳。本文综述了CYP相关药物代谢酶基因多态性的基本知识及其对更安全、更有效药物治疗的临床意义。
